SCOTTSDALE, Ariz., Aug. 13, 2010 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI) has appointed Stephen J. Warner to its Board of Directors effective immediately.
Mr. Warner brings to HEPI a tremendous background that includes being a Managing Director and Co-Founder of Crossbow Ventures Inc., and President/CEO of Merrill Lynch Venture Capital, Inc. Previous to that Mr. Warner was with Arthur D. Little, Inc., and Lockheed Missiles and Space Co. His current interests and obligations have him presently seated as a Director in 5 companies with one of them in the Biotech sector (Dyadic International, Inc.) and another in the medical device sector (AOI Medical).
Mr. Warner obtained his B.S. from MIT (Massachusetts Institute of Technology) and received his MBA from Wharton Graduate School of Business at the University of Pennsylvania, where he graduated 1st in his class.
Mr. Warner stated, "I look forward to being part of the HEPI team and to help realize the significant scientific, health and commercial potential of the ProAlgaZyme ® (PAZ) product."
"We're pleased to have attracted a seasoned public company veteran of Mr. Warner's caliber. His previous experience in the Venture Capital field and his general corporate finance background are invaluable. In addition we have now expanded the Board to include an independent perspective on how we most effectively expand the use of our proprietary PAZ product," stated John Gorman, a HEPI Director. "Mr. Warner is just the first of what we believe will be many strategic steps that HEPI will go through in the near term."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB:HEPI) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme ® (PAZ™) a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme ®.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
For more information, please visit www.heponline.com/" target="_top" rel="nofollow">http://www.heponline.com.